BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34069498)

  • 21. Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.
    Rickert EL; Oriana S; Hartman-Frey C; Long X; Webb TT; Nephew KP; Weatherman RV
    Bioconjug Chem; 2010 May; 21(5):903-10. PubMed ID: 20420372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FRET mechanism between a fluorescent breast-cancer drug and photodynamic therapy sensitizers.
    Lahoz F; Scholz LE; Boto A; Díaz M
    Spectrochim Acta A Mol Biomol Spectrosc; 2020 Oct; 239():118498. PubMed ID: 32470814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
    Wei LL; Mangel WF; Katzenellenbogen BS
    J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.
    Shim JS; Li RJ; Lv J; Head SA; Yang EJ; Liu JO
    Cancer Lett; 2015 Jun; 362(1):106-15. PubMed ID: 25799952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.
    Jameera Begam A; Jubie S; Nanjan MJ
    Bioorg Chem; 2017 Apr; 71():257-274. PubMed ID: 28274582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
    Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol.
    Nelson ER
    Methods Mol Biol; 2016; 1366():431-443. PubMed ID: 26585155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
    Jayaraman S; Reid JM; Hawse JR; Goetz MP
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Selective estrogen receptor modulators (SERMs) in the practice].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.
    Silfen SL; Ciaccia AV; Bryant HU
    Climacteric; 1999 Dec; 2(4):268-83. PubMed ID: 11910661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Molecular Combination of Zinc(II) Phthalocyanine and Tamoxifen Derivative for Dual Targeting Photodynamic Therapy and Hormone Therapy.
    Zhang FL; Song MR; Yuan GK; Ye HN; Tian Y; Huang MD; Xue JP; Zhang ZH; Liu JY
    J Med Chem; 2017 Aug; 60(15):6693-6703. PubMed ID: 28699738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
    Gajdos C; Jordan VC
    Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective estrogen receptor modulation: concept and consequences in cancer.
    Jordan VC
    Cancer Cell; 2004 Mar; 5(3):207-13. PubMed ID: 15050912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.